Hep C advocates alarmed that commercial imperative threatens Gilead/BMS HCV combo
This article was originally published in Scrip
Executive Summary
Patient advocacy groups for hepatitis C patients are considering ways to put pressure on Gilead after hearing reports that a small – but promising - study of interim clinical results of an all-oral combination of Gilead's nucleotide NS5B inhibitor, GS-7977 and Bristol-Myers Squibb's NS5A inhibitor daclatasvir might not progress into Phase III.